• In March 2013, Osprey Medical announced commencement of its US registration directed pivotal IDE clinical study of the CINCOR™ system with the first patient enrolled at the Leipzig Heart Centre in Germany.
  • In May 2013, Dr Richard Heuser enrolled the first two US patients at St. Luke’s Medical Center in Phoenix, Arizona.
  • As of May 31, 2013, twelve hospitals have Institutional Review Board (IRB) and contract approval and are actively screening patients for trial enrollment.
  • The CINCOR dye reduction and removal system limits the amount of dye used in a heart procedure from reaching the kidneys, thereby reducing the risk of Contrast Induced Nephropathy (CIN), a form of acute kidney injury, in patients undergoing common heart procedures.
Osprey Medical (ASX:OSP)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025 Click aqui para mais gráficos Osprey Medical.
Osprey Medical (ASX:OSP)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025 Click aqui para mais gráficos Osprey Medical.